Researchers have shown that antibiotic concentrations can be detected and measured in the exhaled breath of patients receiving intravenous treatment, raising the possibility that a simple breath test could one day replace repeated blood draws for drug monitoring in critical care. A proof-of-concept study involving 10 patients treated with IV antibiotics between 2022 and 2023 found that mass spectrometry could pick up antibiotic-associated metabolites in breath for four out of five drugs tested, including meropenem, cefazolin, and flucloxacillin. The findings, presented at the ESCMID Global Congress 2024, sit alongside a growing body of pilot research suggesting breath analysis could reshape how clinicians track both drug levels and infection clearance in real time.
Detecting Antibiotics in Exhaled Breath
The idea of measuring drugs through breath is not entirely new. Earlier work had established that researchers could detect traces of antibiotics in exhaled air, but those efforts fell short of reliably quantifying drug concentrations. A 2021 report described how scientists moved beyond simple detection to show that antibiotic levels are measurable in breath at concentrations that correlate with blood values. That step was significant because it suggested breath sampling could eventually serve as a practical clinical tool rather than a laboratory curiosity.
The more recent proof-of-concept study, presented as abstract P2422 at ESCMID Global Congress 2024, pushed this work further into a hospital setting. Investigators at a single center enrolled 10 patients who were receiving IV antibiotics and used mass spectrometry to analyze breath for antibiotic-associated metabolites. They detected a clear signal for four out of five antibiotics tested, with meropenem, cefazolin, and flucloxacillin among those successfully identified. The study remains small and single-center, which limits how broadly its results can be applied, but it demonstrates that the analytical chemistry works under real clinical conditions, not just in controlled lab experiments.
From ICU Ventilators to Breath Condensate
A separate line of research has focused specifically on mechanically ventilated patients in intensive care units, where drug monitoring is especially high-stakes. A peer-reviewed pilot study in the Journal of Personalized Medicine showed that beta-lactam antibiotics can be quantified in exhaled condensate collected from ventilated ICU patients. The investigators went a step further by attempting to correlate those breath condensate measurements with epithelial lining fluid concentrations obtained through bronchoalveolar lavage, a more invasive procedure that washes fluid from the lungs to assess local drug levels.
That correlation matters because the goal of antibiotic therapy in pneumonia and other lung infections is to achieve adequate drug concentrations at the site of infection, not just in the bloodstream. Blood draws tell clinicians what is circulating systemically but say little about whether enough drug is reaching the lung tissue where bacteria are actually multiplying. If breath condensate reliably mirrors what is happening in the epithelial lining fluid, it could offer a non-invasive window into local drug delivery. For ICU patients who already endure frequent needle sticks, arterial lines, and other monitoring procedures, replacing even some of those interventions with a breath sample would reduce both discomfort and the risk of secondary infections from repeated vascular access.
Tracking Infection Clearance Through Breath
Measuring drug levels is only half the equation. Clinicians also need to know whether the antibiotic is actually working, which means tracking whether the pathogen is being cleared from the patient’s airways. Research published in the journal Antibiotics demonstrated that electronic nose sensors can detect changes in airway colonization by Staphylococcus aureus in children with cystic fibrosis over time. The eNose technology picks up shifts in volatile organic compound profiles that correspond to changes in microbial burden.
There is an important caveat, however. In that particular study cohort, the sensor changes were unrelated to specific antibiotic treatment. The breath signal tracked bacterial clearance, but the clearance itself appeared to occur independently of the drugs being administered. That disconnect is a reminder that breath-based diagnostics are still in early stages. Detecting a biological change and proving that a specific therapy caused it are two different challenges. Still, the ability to monitor microbial status non-invasively could eventually be paired with drug-level breath tests to give clinicians a more complete picture of both pharmacokinetics and treatment efficacy in a single exhaled sample.
What Treatment Response Looks Like Now
To appreciate what breath testing could change, consider how treatment response is currently assessed in respiratory infections. A review of diagnosis and management of cystic fibrosis exacerbations in Pulmonary Therapy outlines the standard approach: clinicians typically evaluate response at day 7 to 10 of intravenous therapy, using objective measures such as FEV1 change, a lung function metric, alongside patient-reported outcomes like the CRISS score. That timeline means doctors may wait more than a week before they have reliable data on whether a treatment is working.
A week is a long time for a critically ill patient. If the chosen antibiotic is failing, delayed recognition of that failure means prolonged exposure to an ineffective drug, continued bacterial growth, and a narrowing window to switch to a more effective agent. Breath-based monitoring, if validated at scale, could compress that feedback loop. Rather than waiting for a scheduled lung function test days into treatment, clinicians could potentially track drug levels and microbial markers in near-real time, adjusting dosing or switching regimens based on what is happening in the lungs hour by hour.
Building the Evidence Base
Turning proof-of-concept experiments into routine bedside tools will require a much larger and more coordinated evidence base. Many of the early studies have been small, single-center projects, often focused on narrow patient populations. Scaling up will mean standardizing how samples are collected, handled, and analyzed so that results from different hospitals can be compared and pooled. It will also mean validating breath-based measurements against established reference standards such as serum concentrations, bronchoalveolar lavage results, and clinical outcomes like time to defervescence or length of ICU stay.
Large clinical datasets and careful protocol design are central to that effort. Platforms like the National Center for Biotechnology Information host many of the foundational pharmacokinetic and microbiology studies that breath researchers now draw on to design trials and interpret findings. For individual investigators, tools such as personal bibliographies and curated literature collections make it easier to track rapidly evolving work on exhaled biomarkers, antibiotic dosing, and ventilator-associated infections. Even seemingly administrative features, like account and privacy controls in researcher profiles, help support data sharing and collaboration while maintaining appropriate safeguards for patient information.
Regulatory and practical questions will also shape how quickly breath testing moves into practice. Devices must be robust enough for everyday clinical use, not just research labs, and workflows need to fit into already crowded ICU routines. Turnaround time will be critical: a test that takes hours to process may still be useful for dose optimization, but it will not deliver the kind of minute-to-minute feedback that could transform acute decision-making. Cost, reimbursement, and training requirements will further influence adoption.
Looking Ahead to Bedside Breath Tests
Despite these challenges, the trajectory of the field is clear. Early studies have shown that antibiotics and their metabolites can be detected in exhaled breath, that concentrations in condensate can reflect local lung exposure, and that volatile profiles can track shifts in microbial colonization. The next steps will involve integrating these strands into composite assays that report, in a single readout, whether enough drug is reaching the lungs and whether the target pathogen is receding.
If that vision is realized, the clinical impact could be substantial. For ventilated ICU patients, breath tests could reduce the need for repeated blood draws and invasive sampling, while giving clinicians earlier warning when therapy is off track. For patients with chronic lung disease, non-invasive monitoring might allow closer outpatient follow-up and more tailored antibiotic courses, potentially reducing both toxicity and the selective pressure that drives resistance. The work presented at ESCMID Global Congress 2024 and in recent pilot trials does not yet deliver that future, but it offers a credible glimpse of how exhaled breath might become a routine vital sign in antibiotic stewardship and respiratory care.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
